跳至主要内容
临床试验/NCT03655340
NCT03655340已完成不适用

A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France

Swedish Orphan Biovitrum3 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2018年9月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
91
试验地点
3
主要终点
Amount of factor Product used to treat a bleed (on-demand treatment)

研究概览

简要总结

Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Have a diagnosis of haemophilia B and been treated previously with factor IX Product
  • Have started Alprolix treatment prior to enrolment visit, or at enrolment prescribed treatment with Alprolix, regardless of participation in the study
  • Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations

排除标准

  • Participation in an investigational medicinal product trial at enrolment visit

研究组 & 干预措施

Prophylactic patients

Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment

干预措施: Alprolix (Drug)

On demand patients

Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment

干预措施: Alprolix (Drug)

结局指标

主要结局

Amount of factor Product used to treat a bleed (on-demand treatment)

时间窗: 24 months

Assessed by diary

Annualised bleeding rate (ABR) (prophylactic treatment)

时间窗: 24 months

Assessed by diary

Annualised injection frequency (prophylactic treatment)

时间窗: 24 months

Assessed by diary

Number of injections to treat a bleed (on-demand treatment)

时间窗: 24 months

Assessed by diary

Annualised factor consumption (International Unit [IU]) (prophylactic treatment)

时间窗: 24 months

Assessed by diary

次要结局

未报告次要终点

研究者

发起方
Swedish Orphan Biovitrum
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验